Disc Medicine rallies 32% as investors await bitopertin trial results (IRON:NASDAQ)
· seekingalpha.com
Disc Medicine (IRON) shares jumped 32% in premarket trading on Monday ahead of topline results from its Phase 3 APOLLO trial of bitopertin, an experimental treatment for erythropoietic
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...